Sterility, efficiency, and precision: the power of the Blow-Fill-Seal process
Sterile. Single-dose. Practical.
Blow-Fill-Seal (BFS): from process excellence to real-world impact
Discover how Blow-Fill-Seal technology is transforming sterile pharmaceutical manufacturing — from ophthalmology and respiratory products to biologics, vaccines, and orphan medicines.
Download the whitepaper to explore expert insights, real-world use cases, and Unither’s industrial know-how across the entire BFS value chain.
Industrial expertise • Real-world use cases • Expert insights
Why download this whitepaper?
Blow-Fill-Seal goes far beyond a packaging technology. It is a fully integrated aseptic process that directly impacts sterility assurance, cost control, industrial scalability, sustainability, and patient safety.
This whitepaper brings together Unither Pharmaceuticals’ cross-functional expertise — development, quality, regulatory affairs, operations, biologics, and CSR — to deliver a clear, practical, and up-to-date reference on BFS.
- Understand how BFS works and why it has become a reference standard.
- Identify the therapeutic areas where BFS creates the most value.
- Explore the management of complex and temperature-sensitive products (biologics, vaccines).
- Discover the industrial, economic, and environmental performance drivers of BFS.
What you will learn
1. Understanding the Blow-Fill-Seal process
- End-to-end process overview: extrusion, blowing, filling, sealing.
- Rotary vs. linear machines: performance, flexibility, scalability.
- Polymer selection (LDPE, PP, HDPE, PET) and impacts on safety and recyclability.
- Regulatory compliance and extractables & leachables (E&L) strategy.
2. BFS serving therapeutic areas
- Ophthalmology: preservative-free eye drops, sensitive formulations.
- Respiratory & ENT: inhalation solutions, saline solutions.
- Injectables & biologics: vaccines, monoclonal antibodies, Euroject®.
- Orphan drugs: small batches, dose accuracy, vulnerable patients.
- Topical, cosmetic, and wound care applications.
3. Managing temperature-sensitive products
- Advanced temperature control during BFS manufacturing.
- Design of Experiments (DoE) applied to biologics.
- Limiting thermal exposure and preserving molecular integrity.
4. Key advantages of BFS
- Sterile: closed, automated process, reduced contamination risk.
- Single-dose: accurate dosing, patient safety, improved compliance.
- Practical: portability, ease of use, tangible patient benefits.
5. Economic performance & scalability
- High-volume production with consistent quality.
- Reduced components and simplified supply chain.
- Faster scale-up compared with traditional formats.
6. Innovation & sustainability
- BFS for next-generation biologics.
- Euroject®: high-capacity injectable platform, royalty-free.
- Circular economy case study: LDPE recycling at the Gannat site.
- Carbon footprint reduction and eco-design.
Who is this whitepaper for?
- Pharmaceutical companies and biotechs developing sterile liquid dosage forms.
- R&D, CMC, industrialization, and operations teams.
- Decision-makers evaluating BFS as an alternative or complement to vials, prefilled syringes, or multidose systems.
- Organizations seeking scalable, sustainable, and patient-centric industrial solutions.
Why Unither?
With more than 5 billion sterile single doses produced each year, Unither Pharmaceuticals is a global leader in Blow-Fill-Seal, supporting projects from development through to large-scale commercial manufacturing across Europe, the United States, Latin America, and China.
This whitepaper is grounded in real industrial experience, enhanced by insights from Unither’s subject-matter experts.
Do you have a specific project?
Contact our experts to discuss your BFS strategy.